Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -7585.86% is 1656% below its 1-year average of -431.92%, near the low end of its 1-year range (-7585.86%–0.00%).
1656.31% below its 12-month average of -431.92%.
Reported quarterly profit margin; no daily interpolation. Q1 FY2027 (2026-06-30): -2159.61%.
NET PROFIT MARGIN
-7585.86%
NET PROFIT MARGIN AVG TTM
-431.92%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1656.31%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Immunovant, Inc.
Market Cap
$6.84B
Net Profit Margin
-7585.86%
TTM Avg
-431.92%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.72B
Net Profit Margin
10.60%
TTM Avg
11.45%
3Y Avg
11.66%
5Y Avg
12.42%
Market Cap
$6.66B
Net Profit Margin
-5.51%
TTM Avg
7.00%
3Y Avg
-0.29%
5Y Avg
-8.82%
Market Cap
$7.07B
Net Profit Margin
-236.95%
TTM Avg
-945.70%
3Y Avg
-3296.24%
5Y Avg
-3620.73%
Market Cap
$6.53B
Net Profit Margin
17.69%
TTM Avg
17.76%
3Y Avg
15.93%
5Y Avg
7.17%
Market Cap
$6.52B
Net Profit Margin
5.05%
TTM Avg
-0.89%
3Y Avg
-2.79%
5Y Avg
-1.02%
Market Cap
$7.20B
Net Profit Margin
-64.64%
TTM Avg
-52.37%
3Y Avg
-49.29%
5Y Avg
-43.60%
Market Cap
$6.24B
Net Profit Margin
-89.09%
TTM Avg
-187.61%
3Y Avg
-9430.16%
5Y Avg
-6286.77%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.84B | -7585.86% | -431.92% | 0.00% | 0.00% |
| Chemed Corporation (CHE)vs › | $6.72B | 10.60% | 11.45% | 11.66% | 12.42% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.66B | -5.51% | 7.00% | -0.29% | -8.82% |
| Alkermes plc (ALKS)vs › | $7.03B | 3.97% | 19.97% | 11.77% | 5.39% |
| GRAIL Inc. (GRAL)vs › | $7.07B | -236.95% | -945.70% | -3296.24% | -3620.73% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 17.69% | 17.76% | 15.93% | 7.17% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 5.05% | -0.89% | -2.79% | -1.02% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.20B | -64.64% | -52.37% | -49.29% | -43.60% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.24B | -89.09% | -187.61% | -9430.16% | -6286.77% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.11B | 67.88% | 22.01% | 16.68% | 14.76% |
Operating Margin
0.0%
Net Profit Margin
-7585.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -2159.61% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
